Appili Therapeutics Appoints Drug Development Executive as Chief Development Officer

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF), a biopharmaceutical company developing anti-infective drug candidates, today announced it has recruited Don Cilla, PharmD, MBA, to serve as the company's new chief development officer (CDO), effective November 1, 2020.

In this role, Dr. Cilla will oversee the strategy and execution of the preclinical and clinical programs for Appili's anti-infective pipeline. He will be responsible for advancing programs through clinical development, regulatory submission, and commercialization milestones. He brings more than 30 years of experience in the drug development industry spanning large, midsize, and start-up companies, with extensive global clinical development and regulatory expertise.   

Read the company's release.

Appili Therapeutics is an Innovacorp portfolio company.

October 29, 2020, Halifax, Nova Scotia